Agomelatine

🧮 Dose calculator

Major depressive disorder · Regimen source: eMC Valdoxan · 4.2

• • Liver tests before starting and at about 3, 6, 12 and 24 weeks; do not start (and stop) if transaminases exceed 3× ULN. Increase to 50 mg only with strict liver monitoring. eMC Valdoxan · 4.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. eMC Valdoxan · 4.6

  “There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of agomelatine in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. eMC Valdoxan · 4.6

  “Available pharmacodynamic/toxicological data in animals have shown excretion of agomelatine/metabolites in milk (see section 5.3).”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. eMC Valdoxan · 4.2

  “Children and adolescents from 7 to 17 years The safety and efficacy of agomelatine in children and adolescents aged from 7 to 17 years for treatment of major depressive episodes have not been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. eMC Valdoxan · 4.2

  “No dose adjustment is required in relation to age (see section 5.2).”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.